Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11157
Title: Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
Authors: Grossmann, Mathis;Zajac, Jeffrey D
Affiliation: Department of Medicine, Austin Health/Northern Health, University of Melbourne, Heidelberg, Victoria, Australia. mathisg@unimelb.edu.au
Issue Date: 1-Mar-2011
Citation: Clinical Endocrinology; 74(3): 289-93
Abstract: Adverse effects of androgen deprivation therapy (ADT) are a consequence of the induced sex steroid deficiency. ADT increases fat mass leading to insulin resistance and diabetes, and accelerates bone loss causing increased fracture risk. Given the high prevalence of cardiovascular disease and reduced bone density in ADT-naïve men with prostate cancer, the benefits of ADT have to be carefully weighed against its side effects, especially as a diagnosis of prostate cancer does not alter the life expectancy for most men. Men commencing ADT should be counselled about and be carefully monitored for these and other ADT-induced complications, which include fatigue, sexual dysfunction, hot flushes and anaemia. ADT-associated side effects should be prevented and treated in order that ADT-induced toxicity does not outweigh its benefits. Future clinical trials are needed: first, to better define the effects of ADT on survival in men with localized prostate cancer or with biochemical prostate-specific antigen recurrence; second, to delineate ADT-associated harm, especially with respect to cardiovascular events and fractures; and third, to test the efficacy of interventions designed to minimize ADT-related adverse outcomes. Such information will be essential to better quantify the risk-benefit ratio of ADT in the individual man with prostate cancer.
Internal ID Number: 21092052
URI: http://ahro.austin.org.au/austinjspui/handle/1/11157
DOI: 10.1111/j.1365-2265.2010.03939.x
URL: http://www.ncbi.nlm.nih.gov/pubmed/21092052
Type: Journal Article
Subjects: Androgen Antagonists.adverse effects.therapeutic use
Antineoplastic Agents, Hormonal.adverse effects.therapeutic use
Cardiovascular Diseases.diagnosis.prevention & control
Drug-Related Side Effects and Adverse Reactions.diagnosis.prevention & control
Fractures, Bone.prevention & control
Humans
Male
Prostatic Neoplasms.drug therapy
Quality of Life
Risk Assessment
Risk Factors
Treatment Outcome
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.